XML 47 R39.htm IDEA: XBRL DOCUMENT v3.23.1

Segment Information (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Schedule of segment information

		During the Three-Month Period Ended March 31, 2023
		Scours				Mastitis				Other				Total
Product sales		$	3,411,232			$	35,295			$	—			$	3,446,527
Costs of goods sold			3,103,958				41,794				—				3,145,752
Gross margin			307,274				(6,499	)			—				300,775
Product development expenses			291				1,076,344				33,733				1,110,368
Sales and marketing expenses			690,544				188,883				—				879,427
Administrative expenses			—				—				567,019				567,019
Operating expenses			690,835				1,265,227				600,752				2,556,814
NET OPERATING LOSS		$	(383,561	)		$	(1,271,726	)		$	(600,752	)		$	(2,256,039	)

		During the Three-Month Period Ended March 31, 2022
		Scours				Mastitis				Other				Total
Product sales		$	5,962,875			$	35,427			$	1,382			$	5,999,684
Costs of goods sold			2,852,329				26,803				17,329				2,896,461
Gross margin			3,110,546				8,624				(15,947	)			3,103,223
Product development expenses			8,416				982,129				45,390				1,035,935
Sales and marketing expenses			418,667				392,833				—				811,500
Administrative expenses			—				—				685,179				685,179
Operating expenses			427,083				1,374,962				730,569				2,532,614
NET OPERATING INCOME (LOSS)		$	2,683,463			$	(1,366,338	)		$	(746,516	)		$	570,609

		Scours				Mastitis				Other				Total
Total Assets as of March 31, 2023		$	21,519,208			$	18,253,991			$	3,349,988			$	43,123,187
Total Assets as of March 31, 2022		$	15,654,608			$	18,951,158			$	12,093,730			$	46,699,496
Depreciation and amortization expense during the three-month period ended March 31, 2023		$	323,257			$	317,624			$	17,948			$	658,829
Depreciation and amortization expense during the three-month period ended March 31, 2022		$	292,792			$	315,008			$	15,728			$	623,528
Capital Expenditures during the three-month period ended March 31, 2023		$	571,736			$	110,430			$	—			$	682,166
Capital Expenditures during the three-month period ended March 31, 2022		$	726,721			$	80,775			$	—			$	807,496

		During the Year Ended December 31, 2022
		Scours				Mastitis				Other				Total
Product sales		$	18,411,949			$	154,558			$	1,455			$	18,567,962
Costs of goods sold			10,754,189				136,347				28,647				10,919,183
Gross margin			7,657,760				18,211				(27,192	)			7,648,779
Product development expenses			66,346				4,317,921				109,605				4,493,872
Sales and marketing expenses			1,871,926				1,318,107				—				3,190,033
Administrative expenses			—				—				2,263,817				2,263,817
Operating expenses			1,938,272				5,636,028				2,373,422				9,947,722
NET OPERATING INCOME (LOSS)		$	5,719,488			$	(5,617,817	)		$	(2,400,614	)		$	(2,298,943	)

		During the Year Ended December 31, 2021
		Scours				Mastitis				Other				Total
Product sales		$	18,933,092			$	143,280			$	166,597			$	19,242,969
Costs of goods sold			10,411,936				99,957				75,147				10,587,040
Gross margin			8,521,156				43,323				91,450				8,655,929
Product development expenses			25,374				3,887,781				255,363				4,168,518
Sales and marketing expenses			1,942,391				561,535				—				2,503,926
Administrative expenses			—				—				1,726,100				1,726,100
Operating expenses			1,967,765				4,449,316				1,981,463				8,398,544
NET OPERATING INCOME (LOSS)		$	6,553,391			$	(4,405,993	)		$	(1,890,013	)		$	257,385

		Scours				Mastitis				Other				Total
Total Assets as of December 31, 2022		$	20,539,523			$	18,315,492			$	6,005,634			$	44,860,649
Total Assets as of December 31, 2021		$	14,860,769			$	19,122,265			$	10,482,654			$	44,465,688
Depreciation and amortization expense during the year ended December 31, 2022		$	1,169,011			$	1,263,318			$	62,912			$	2,495,241
Depreciation and amortization expense during the year ended December 31, 2021		$	1,032,735			$	1,374,171			$	62,075			$	2,468,981
Capital Expenditures during the year ended December 31, 2022		$	3,513,336			$	414,486			$	47,452			$	3,975,274
Capital Expenditures during the year ended December 31, 2021		$	1,632,855			$	975,794			$	—			$	2,608,649

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration